← 返回

卵巢高级别浆液性癌腹水细胞块肿瘤细胞簇上 CD8 阳性淋巴细胞的临床意义

英文原题:Clinical significance of CD8-positive lymphocytes on tumor cell clusters of ascites cell block in ovarian high-grade serous carcinoma.

查看英文原题

Clinical significance of CD8-positive lymphocytes on tumor cell clusters of ascites cell block in ovarian high-grade serous carcinoma.

PubMed 2022/02/08(内容时间) Cancer Med Q2 · IF 3.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

腹水中肿瘤细胞簇中 CD8+淋巴细胞的存在与 HGSC 患者组织中的免疫反应状态及预后相关,可能为免疫相关治疗提供有用信息。

研究思路结论见上方概要

研究了卵巢高级别浆液性癌(HGSC)患者腹水细胞块中肿瘤细胞簇上CD8阳性(CD8+)淋巴细胞的临床意义。

在2014年1月至2019年12月接受手术的HGSC患者中,选取了38例有腹水细胞块的患者。使用这些细胞块和原发性卵巢肿瘤组织,通过免疫组化检测CD8+淋巴细胞的存在和PD-L1的表达。肿瘤细胞簇定义为细胞块中由10个以上恶性细胞组成的细胞团。肿瘤细胞簇中至少有1个CD8+淋巴细胞的病例定义为CD8+淋巴细胞阳性(A组);其他定义为CD8+淋巴细胞阴性(B组)。肿瘤组织CD8+淋巴细胞通过机械计数。回顾性比较两组的临床病理特征。

共识别出38例:A组25例(65.8%),B组13例(34.2%)。A组中CD4(p < 0.01)、PD-L1(p = 0.02)、FoxP3(p = 0.02)阳性病例更多,且组织内CD8 + 淋巴细胞数量更高(p = 0.03)。A组患者的无进展生存期(p < 0.01)和总生存期(p = 0.04)更好。在多变量分析中,A组是无进展生存期(风险比,0.24;p < 0.01)和总生存期(风险比,0.21;p = 0.03)的独立预后因素。

展开英文摘要原文

The clinical significance of CD8-positive (CD8 + ) lymphocytes on tumor cell clusters of ascites cell blocks in patients with ovarian high-grade serous carcinoma (HGSC) was investigated.

Among HGSC patients who underwent surgery from January 2014 to December 2019, 38 patients with ascites cell block were selected. Using these cell blocks and primary ovarian tumor tissue, the presence of CD8 + lymphocytes and the expression of PD-L1 were examined immunohistochemically. Tumor cell clusters were defined as cell clumps consisting of more than 10 malignant cells in cell block. Cases with at least one CD8 + lymphocyte in tumor cell cluster were defined as positive CD8 + lymphocytes (Group A); others were defined as negative CD8 + lymphocytes (Group B). The tumor tissue CD8 + lymphocytes were counted mechanically. Clinicopathological features were retrospectively compared between the two groups.

In total, 38 cases were identified: 25 (65.8%) in Group A and 13 (34.2%) in Group B. More cases in Group A were positive for CD4 (p < 0.01), PD-L1 (p = 0.02), FoxP3 (p = 0.02) and had a higher number of CD8 + lymphocytes in the tissue (p = 0.03). Patients in Group A had better progression-free survival (p < 0.01) and overall survival (p = 0.04). In multivariate analysis, Group A was an independent prognostic factor for both progression-free survival (hazard ratio, 0.24; p < 0.01) and overall survival (hazard ratio, 0.21; p = 0.03).

The presence of CD8 + lymphocytes in tumor cell clusters of ascites was associated with the status of immune reaction in the tissue and prognosis in patients with HGSC and might be useful information of the immune-associated therapy.

论文信息

作者
Iwahashi H、Miyamoto M、Ito T、Suminokura J、Hada T、Ishibashi H、Kakimoto S、Matsuura H
单位
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Japan.Japan
期刊
Cancer medicine2022 May
原文标识
PubMed 35137571 · DOI 10.1002/cam4.4592